ProMIS Neurosciences Inc PMN

2021 report

[retiredcop]

https://stockhouse.com/news/press-releases/2022/03/17/promis-neurosciences-announces-fiscal-year-2021-results

[M101]

"The top priority...ALS...PMN267...initial data in the first half of 2022." Like

[Mole101]

  Not sure my portfolio feels the same ...;( 2021 was an excellent year for ProMIS including strong capital formation which enabled us to advance and expand our portfolio of differentiated therapeutic product candidates such as Alzheimer’s disease (AD), ALS, and Schizophrenia,” said Gene Williams, ProMIS’ Chairman and CEO....  

[Gbathat]

Here are some of the comments from the annual report that I thought were interesting: " While biotechnology markets and specific disease sectors within biotechnology have cyclical ups and downs, we are well positioned to continue making substantive progress in our programs that could allow us to capitalize when markets rebound, as we believe they will." Is this referring to biogen

[M101]

Got to keep the Biogen/ACH blame game going because it sure isn't biotech generally: https://www.labiotech.eu/trends-news/biotech-investment-firms-fund/  https://www.mckinsey.com/industries/life-sciences/our-insights/whats-ahead-for-biotech-another-wave-or-low-tide

[FarmerBetty]

Yes, this quarter our cash is sufficient to finance the company's operations through the end of 2023. Last quarterly report our cash will finance the company's operations into 2024, slowly moving the goal post for more financing. The fact they mentioned as a high light for last year the June Propectus to raise up to 50 million US is where they might be headed. It is not about creating

[M101]

If they do a financing before earliest P1 interim results that will prove your point, IMO, because of all the biomarker talk. So this is a reason to scrutinze the P1 plan.